Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 103Neoplasms, Plasma Cell 11Immunoglobulin Light-chain Amyloidosis 11Recurrence 10Leukemia, Myeloid, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 3Neoplasms 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Smoldering Multiple Myeloma 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Hodgkin Disease 2Hematologic Diseases 2Corneal Diseases 2Blood Protein Disorders 2Amyloidosis 2Acute Kidney Injury 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Plasmacytoma 1

Interventions

Cyclophosphamide 26fludarabine 16Etoposide 15Melphalan 13romidepsin 12Gemcitabine 11Whole-Body Irradiation 10Vincristine 10Peripheral Blood Stem Cell Transplantation 10Doxorubicin 10fludarabine phosphate 9Rituximab 9Lenalidomide 9Cytarabine 9Busulfan 9pembrolizumab 8Prednisone 8Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Bortezomib 8Filgrastim 7Carmustine 7Brentuximab Vedotin 7Biopsy 7duvelisib 6Tacrolimus 6Specimen Handling 6Dexamethasone 6Bendamustine Hydrochloride 6ruxolitinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell × daratumumab × Clear all
NCT04251065 2025-03-28

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Fondazione Italiana Linfomi - ETS

Phase 2 Terminated
8 enrolled 17 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡